Objective Hepatocellular carcinoma (HCC) has become a pressing health problem facing
the world today due to its high morbidity, high mortality, and late discovery. As a diagnostic …

Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality worldwide.
Early detection of HCC enables patients to avail curative therapies that can improve patient …

Background & Aims Prothrombin induced by vitamin K absence-II (PIVKA-II) is a diagnostic
and surveillance marker for HCC mainly used in Asia, and has also been shown to be a …

The limited performance of guideline‐recommended abdominal ultrasound and serum
alpha‐fetoprotein (AFP) highlights the urgent, unmet need for new biomarkers for more …

Background & Aims GALAD and BALAD-2 are statistical models for estimating the likelihood
of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver …

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of death in
cirrhotic patients worldwide. The detection rate for early stage HCC remains low despite …

Despite vaccination programs and direct antiviral treatments, the incidence of virus-related
hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for …

Hepatocellular carcinoma (HCC) is an increasing health problem, representing the second
cause of cancer-related mortality worldwide. The major risk factor for HCC is cirrhosis. In …

Abstract Background & Aims Protein induced by vitamin K absence or antagonist‐II (PIVKA‐
II) has been suggested as a serum biomarker for hepatocellular carcinoma (HCC) in Asian …

Biomarkers for surveillance, diagnosis and prediction of prognosis in patients with
hepatocellular carcinoma (HCC) are currently not ready for introduction into clinical practice …